



Follow up and lab schedule FTM

This is in addition to any other indicated lab monitoring based on other risks or disease states.

	All	Age > 30 or ↑risk of CVD	Age > 40	Age > 50	Based on Risks/Organs
Baseline	CBC, fasting CMP, BP	Lipids	chest/breast exam, Mammo if not s/p mastectomy		Pap ^{[1][2]} , STI screen ^[3] , HCG if has uterus
2-3 mos p start or dose change	CBC, fasting glucose, ALT, Lipids, BP, Trough Total Testosterone				
Q6 months ^[1]	BP and exam				
Q12 months (stable dose)	CBC, fasting glucose, ALT, BP, Trough Total Testosterone	Lipids	chest/breast exam, Mammo if not s/p mastectomy	Consider osteoporosis screening if on testosterone > 5 yrs	Pap ^{[2][3]} , STI screen ^[4]

[1] In selected otherwise healthy FTM patients on a stable dose for a year or more, visits may be extended to once annually.

[2] Consider HPV testing if age > 30 or if significant emotional stress around pelvic exam so that q2-3 year screening may be done

[3] Let pathologist know if patient is on testosterone

[4] STI Screen = HIV, RPR, Hep A/B/C, GC/CT and consider Hep A/B vaccination

FTM Medication

Dose may be decreased after oophorectomy, but not in all cases

Hormones^[1]

Medication	Start	Mid	Max
Testosterone cypionate	50 mg q 2 weeks	150 mg q 2 weeks	250 mg q 2 weeks
Testosterone enanthate	50 mg q 2 weeks	150 mg q 2 weeks	250 mg q 2 weeks
Androderm Patch	2 mg/patch qd	4 mg/patch qd	10 mg/patch qd
Androgel / Testim 1% gel	2.5 g qd	5 g qd	10 g qd
Testosterone 5% cream (compounded)	0.25 g qd	1 g qd	2 g qd

[1] Adjust dose every 2-3 months to achieve desired changes and/or bring trough testosterone to lower half of male range

Follow up and lab schedule MTF

This is in addition to any other indicated lab monitoring based on other risks or disease states.

	All	Spiro	Flutamide	Age > 30 or ↑risk of CVD	Age > 40	Age > 50	Based on Risks/Organs
Baseline	CBC, CMP BP		G6PD, consider MetHgb level if G6PD deficient or smoker	Lipids	Mammo if high-risk family history	Digital rectal exam, Consider PSA if high-risk	STI screen ^[1]
2-3 mos p start or dose change	CBC, ALT, Lipids, BP, Prolactin	K+, Cr	LFT, consider MetHgb if risks	Lipids			
Q6 months	CBC, ALT, BP, Prolactin, Consider Total Testosterone if inadequate feminization	K+, Cr					
Q12 months (stable dose)	CBC, ALT, BP, Prolactin	K+, Cr		Lipids		Digital rectal exam; Mammo if > 5 yrs on hormones or high-risk family history	STI screen ^[1] , Pap smear ^{[2] [3]}

[1] STI Screen = HIV, RPR, Hep A/B/C, GC/CT and consider Hep A/B vaccination

[2] After vaginoplasty, do vaginal pap smear if history of genital warts and cervical pap smear if has neocervix

[3] Let pathologist know if patient is on estrogen

MTF Medication

Daily dose listed for oral preps; dividing bid recommended for those at risk of liver toxicity

Hormones^{[1] [2]}

Medication/Orchi status	Start	Mid	Max
Premarin / Pre	2.5 mg	5 mg	10 mg
Premarin / Post	1.25 mg		5 mg
Estradiol / Pre	1 mg	4 mg	6 mg
Estradiol / Post	1 mg		4 mg
Estradiol valerate / Pre	20 mg q 2 weeks	40 mg q 2 weeks	60 mg q 2 weeks
Estradiol valerate / Post	20 mg q 2 weeks		40 mg q 2 weeks
Estradiol patch / Pre	0.1 mg/d biw	0.2 mg/d biw	0.3 mg/d biw
Estradiol patch / Post	0.0375 mg/d biw		0.2 mg/d biw

Anti-Androgens^[3]

Medication/Orchi status	Start	Mid	Max
Sprinolactone ^{[4] [5]}	50 mg qd	200 mg qd	500 mg qd
Flutamide ^[4]		125 mg bid	
Finasteride / Pre	2.5 mg qd	5 mg qd	5 mg qd
Finasteride / Post (androgenic alopecia)		1 - 1.25 mg qd	5 mg qd
Medroxyprogesterone (not routinely recommended) ^[4]	2.5 mg qd	5 mg qd	10 mg qd

Other

Medication	Start	Mid	Max
Aspirin if high risk CVD		81 mg qd	

[1] Adjust dose every 2-3 months to achieve desired changes; check testosterone levels if desired effects are not achieved at max doses

[2] Discontinue hormones 2-4 weeks prior to any major surgery to reduce the risk of thromboembolic events

[3] Spironolactone should be first-line anti-androgen

[4] Generally only used pre-orchietomy

[5] Can be divided bid